2024-09-11 - Analysis Report
## MRK Stock Analysis Report

**Company Overview:**

MRK, or Merck & Co., Inc., is a global pharmaceutical company that researches, develops, manufactures, and markets a broad range of prescription medicines, vaccines, and animal health products.

**Performance Analysis:**

**1. Performance vs. S&P 500 (VOO):**

* **Cumulative Return:** MRK's cumulative return is 48.71% compared to VOO's 83.37%.
* **Relative Divergence:** MRK currently lags behind VOO by -34.66%, representing a relative divergence of 40.54% based on historical data. This signifies that MRK's performance is currently below the average compared to VOO's performance over time.

**2. Recent Price Fluctuation:**

* **Closing Price:** $115.41
* **5-Day Moving Average:** $116.84
* **20-Day Moving Average:** $115.87
* **60-Day Moving Average:** $121.55

The 5-day moving average is slightly higher than the current price, suggesting potential short-term bearish sentiment. However, both the 20-day and 60-day moving averages are higher than the current price, indicating a potential long-term upward trend. 

**3. Technical Indicators:**

* **RSI:** 53.72
* **PPO:** 0.36
* **Delta_Previous_Relative_Divergence:** -3.55 (indicating short-term bearish sentiment)
* **Expected Return:** 11.43% (estimated 5-year potential return for current investment)

The RSI indicates a slightly overbought condition, while the positive PPO suggests a potential upward trend. The negative Delta_Previous_Relative_Divergence, however, points to a short-term bearish sentiment. The relatively high expected return could be attractive for long-term investors.

**4. Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-05 | 2.15 | 16.11 B$ |
| 2024-05-03 | 1.88 | 15.78 B$ |
| 2023-11-03 | 1.87 | 15.96 B$ |
| 2023-08-07 | -2.35 | 15.04 B$ |
| 2024-08-05 | -2.35 | 15.04 B$ |

**Most recent earnings:** 

The most recent earnings for Q2 2024 were reported on August 5th, 2024. EPS was $2.15, exceeding analysts' expectations of $1.92. Revenue came in at $16.11 billion, exceeding expectations of $15.87 billion. This strong performance reflects the company's positive trajectory and market position. 

**5. Summary:**

MRK has shown strong recent earnings and continues to demonstrate a robust market position. While its cumulative return currently lags behind the S&P 500, the company shows potential for future growth, backed by a positive outlook and a high expected return. However, the short-term technical indicators suggest caution as the market currently favors a bearish sentiment. 

**6. Conclusion:**

Overall, MRK presents an intriguing opportunity for investors seeking exposure to the pharmaceutical sector. The company boasts a solid track record, strong recent performance, and a bright future outlook. While the short-term technical indicators suggest potential bearish momentum, the company's long-term prospects remain promising. Investors considering MRK should carefully weigh the current market sentiment and potential risks before making any investment decisions. 
